SRSF1 and glioblastoma: In addition, we found that SRSF1 may be also used as prognostic factor in GBM patients: Kaplan–Meier survival analysis showed that GBM patients who exhibited high immunoexpression of SRSF1 had lower OS times than those with low immunoexpression (median OS of 18.0 months vs. 23.0 months).